Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
19 mai 2022 08h15 HE
|
Clearmind Medicine Inc.
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Announces Pre-IND Meeting Date with FDA
13 mai 2022 09h30 HE
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end Vancouver, May 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or...
Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors
10 mai 2022 08h30 HE
|
Clearmind Medicine Inc.
Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals
09 mai 2022 09h30 HE
|
Clearmind Medicine Inc.
Prof. Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses; Prof. Weiser specializes in psychiatric disorders such...
Clearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th
24 mars 2022 15h00 HE
|
Clearmind Medicine Inc.
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the...
Clearmind Medicine Announces Positive Results on CMND-100 trials
17 mars 2022 08h00 HE
|
Clearmind Medicine Inc.
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Clearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
08 mars 2022 08h30 HE
|
Clearmind Medicine Inc.
The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE...
Clearmind Medicine to Host a "Psychedelics for Alcoholism" Event for Investors on February 23
17 févr. 2022 09h00 HE
|
Clearmind Medicine Inc.
Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for alcohol use disorder TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine announces Share-Based Compensation Plan
09 févr. 2022 17h30 HE
|
Clearmind Medicine Inc.
TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the...
Clearmind Medicine Secures CAD$1.6 Million in Private Placement
08 févr. 2022 07h30 HE
|
Clearmind Medicine Inc.
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the...